Sato Yoshiki, Doden Kenji, Nishida Yoji, Shimizu Satsuki, Tanaka Nobuhiro, Yagi Daisuke, Asaumi Yoshihide, Hirano Yasumitsu, Maeda Kazuya, Miyanaga Tamon, Hattori Masakazu, Hashizume Yasuo
Dept. of Surgery, Fukui Prefectural Hospital, Japan.
Gan To Kagaku Ryoho. 2013 May;40(5):647-50.
We report our experience with a case of colorectal cancer treated with chemotherapy for a liver metastasis patient on hemodialysis. The patient was a 67-year-old man with a history of chronic renal failure, who was on hemodialysis since 2005. High anterior resection was performed for sigmoid colon and rectal cancer in January, 2010. After starting chemotherapy while planning to use FOLFOX6+bevacizumab(BV)as a postoperative standard chemotherapy, in combination with hemodialysis three times a week while performing dose escalation, administration postponement was continued for myelosuppression that was considered to be the effect of oxaliplatin. Oxaliplatin was administered for only 2 courses, and was then changed to BV+sLV5FU2 therapy. We continued treating the metastases approximately on schedule. Imaging revealed, the liver metastases were CR because they had disappeared. The BV use case of the dialysis case had few reports, but was thought to be able to use it by careful administration safely.
我们报告了对一名接受血液透析的肝转移结直肠癌患者进行化疗的经验。该患者为67岁男性，有慢性肾衰竭病史，自2005年起接受血液透析。2010年1月对乙状结肠癌和直肠癌进行了高位前切除术。在开始化疗时，计划使用FOLFOX6+贝伐单抗（BV）作为术后标准化疗，同时每周进行三次血液透析并逐步增加剂量，但因考虑到骨髓抑制是奥沙利铂的作用而持续推迟给药。奥沙利铂仅给药2个疗程，然后改为BV+sLV5FU2治疗。我们大致按计划继续治疗转移灶。影像学检查显示，肝转移灶已消失，达到完全缓解（CR）。关于透析患者使用BV的病例报道较少，但认为通过谨慎给药可以安全使用。
